Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
June 07, 2021 07:30 ET
|
Translate Bio, Inc.
-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to...
Translate Bio to Participate in Upcoming Investor Conferences
May 24, 2021 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference
May 18, 2021 10:00 ET
|
Translate Bio, Inc.
– Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations – – Company expects to advance a lead PCD candidate into...
Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:13 ET
|
Translate Bio, Inc.
-- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 05, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit
April 28, 2021 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 20, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines
April 19, 2021 07:30 ET
|
Translate Bio, Inc.
-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy...
Translate Bio Announces Key Leadership Additions and Promotions
April 19, 2021 07:30 ET
|
Translate Bio, Inc.
-- Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringingstrategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 07, 2021 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...